Pollack, C., Reilly, P. A., Verhamme, P., Bernstein, R., Dubiel, R., Eikelboom, J., … Weitz, J. (2015). Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 13, 85–85.

Pollack, C., P. A. Reilly, P. Verhamme, R. Bernstein, R. Dubiel, J. Eikelboom, M. Huisman, et al. “Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions.” JOURNAL OF THROMBOSIS AND HAEMOSTASIS 13 (June 1, 2015): 85–85.

Pollack C, Reilly PA, Verhamme P, Bernstein R, Dubiel R, Eikelboom J, et al. Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2015 Jun 1;13:85–85.

Pollack, C., et al. “Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions.” JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 13, WILEY-BLACKWELL, June 2015, pp. 85–85.

Pollack C, Reilly PA, Verhamme P, Bernstein R, Dubiel R, Eikelboom J, Huisman M, Hylek E, Kam C-W, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Steiner T, Wang B, Weitz J. Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. WILEY-BLACKWELL; 2015 Jun 1;13:85–85.